Literature DB >> 16707201

Correlation between plasma levels of glutamate, alanine and serine with severity of depression.

Hideaki Mitani1, Yukihiko Shirayama, Takeshi Yamada, Kazuhisa Maeda, Charles R Ashby, Ryuzou Kawahara.   

Abstract

The goal of this study was to evaluate the utility of using plasma levels of amino acids as an indicator of the severity of depression. The samples were collected from 23 depressed patients receiving antidepressant medication, and were compared to 31 healthy subjects. The plasma levels of amino acids were determined using HPLC with fluorometric detection. The severity of depression was evaluated using the Hamilton Depression Rating Scale (HAM-D) scores. Plasma levels of glutamate, glutamine, glycine and taurine were significantly increased in the depressed patients compared to the controls. Statistical analysis indicated a positive correlation between glutamate and alanine levels and HAM-D scores and a negative correlation of L-serine with HAM-D scores. The results indicate that plasma level of glutamate, alanine and L-serine could reflect the severity of depression rather than glutamine, glycine and taurine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707201     DOI: 10.1016/j.pnpbp.2006.03.036

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  86 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Neuroinflammation and comorbidity of pain and depression.

Authors:  A K Walker; A Kavelaars; C J Heijnen; R Dantzer
Journal:  Pharmacol Rev       Date:  2013-12-11       Impact factor: 25.468

Review 3.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

4.  GABAergic control of depression-related brain states.

Authors:  Bernhard Luscher; Thomas Fuchs
Journal:  Adv Pharmacol       Date:  2015-01-14

Review 5.  Can Neurochemical Changes of Mood Disorders Explain the Increase Risk of Epilepsy or its Worse Seizure Control?

Authors:  Andres M Kanner
Journal:  Neurochem Res       Date:  2017-07-01       Impact factor: 3.996

6.  The effect of pyruvate on the development and progression of post-stroke depression: A new therapeutic approach.

Authors:  Dmitry Frank; Ruslan Kuts; Philip Tsenter; Benjamin F Gruenbaum; Yulia Grinshpun; Vladislav Zvenigorodsky; Ilan Shelef; Dmitry Natanel; Evgeny Brotfain; Alexander Zlotnik; Matthew Boyko
Journal:  Neuropharmacology       Date:  2019-05-31       Impact factor: 5.250

7.  Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male mice.

Authors:  Younghyurk Lee; Hyeonwi Son; Gyeongwha Kim; Sujeong Kim; Dong Hoon Lee; Gu Seob Roh; Sang Soo Kang; Gyeong Jae Cho; Wan Sung Choi; Hyun Joon Kim
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

8.  Possible Role of Platelet GluR1 Receptors in Comorbid Depression and Cardiovascular Disease.

Authors:  Hu Chen
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-08-16

9.  Serum glutamine, set-shifting ability and anorexia nervosa.

Authors:  Michiko Nakazato; Kenji Hashimoto; Ulrike Schmidt; Kate Tchanturia; Iain C Campbell; David A Collier; Masaomi Iyo; Janet Treasure
Journal:  Ann Gen Psychiatry       Date:  2010-06-25       Impact factor: 3.455

10.  Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.

Authors:  Márcio Gerhardt Soeiro-de-Souza; Giacomo Salvadore; Ricardo Alberto Moreno; Maria Concepción Garcia Otaduy; Kalil T Chaim; Wagner F Gattaz; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.